In patients with heart failure and aortic stenosis, the complement system is overactive. Complement activity is also linked to prognosis, shows Negar Shahini’s PhD thesis.
MAIN RESULTS:
THESIS DEFENCE:
Thesis: Dysregulation of the complement system in cardiac disease – clinical and experimental studies
Candidate: Negar Shahini
Time: December 10, 2018 at 12:15
Place: Oslo University Hospital, Rikshospitalet B: Seminar room 2
Link to university website
SUMMARY:
The complement system is an important part of our innate immune system. Uncontrolled complement activation leads to extensive inflammation and tissue damage. The complement system can be activated through three different signalling pathways, and the alternative pathway is the focus of Shahini’s PhD thesis.
(1) Factor D, factor B and the terminal complement complex (TCC) are increased in heart failure patients. Factor D is a specific activator of the alternative pathway, whereas TCC and factor B are full system activators. On the other hand, the alternative complement promoter properdin was decreased, especially in the most severely affected patients. Low levels of properdin were also significantly associated with worse prognosis, but not significantly so after adjustments for covariates. Low levels of the alternative complement inhibitor factor H, however, were independently linked to increased risk of death or heart transplantation.
The levels of the complement components were evaluated in 188 patients with chronic heart failure and compared to 67 age- og sex-matched healthy persons. The patients were followed for a median of 4.6 years.
(2) Patients with symptomatic aortic stenosis have increased complement activation. The levels of TCC were higher than in healthy control persons. Moreover, elevated levels of factor B were linked to increased risk of major cardiovascular events and all-cause mortality.
(3) Complement component 3 and CD14 does not seem to be directly involved in cardiac remodelling. In a murine model of cardiac pressure overload induced by angiotensin II, deficiency in these two bottleneck molecules in pattern recognition did not affect progression of cardiac remodelling.
REFERENCES:
(1) Shahini, N., Michelsen, A. E., Nilsson, P. H., Ekholt, K., Gullestad, L., Broch, K., Dahl, C. P., Aukrust, P., Ueland, T., Mollnes, T. E., Yndestad, A., & Louwe, M. C. (2017). The alternative complement pathway is dysregulated in patients with chronic heart failure. Scientific Reports, 7, 42532.
- priority at NORHEART events
- visibility to other cardiovascular researchers
- e-mail updates and Newsletter
- membership free of charge
Join the Friends of NORHEART mailing list if you want to receive our newsletter without membership.
More than 100 participants attended the 22nd Annual Norwegian Symposium on Heart Research, hosted by…
Approximately 25 researchers met in Trondheim for the new workshop called “Advancing Ischemic Heart Disease…
Cardiac researchers and clinical cardiologists need to know key concepts and terms for measuring and describing…
The Norwegian Health Association has awarded the prestigious 2024 Heart Research Award (Hjerteforskningsprisen) to professor Kristina…